gemfibrozil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1285	25812-30-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: gemfibrosil gemfibrozil decrelip lopizid	A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. Molecular weight: 250.34 Formula: C15H22O3 CLOGP: 3.94 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 46.53 ALOGS: -3.95 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

gemfibrosil
gemfibrozil
decrelip
lopizid

A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.

Molecular weight: 250.34
Formula: C15H22O3
CLOGP: 3.94
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 46.53
ALOGS: -3.95
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.02 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	79.89 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	98 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Dec. 21, 1981	FDA	PFIZER PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rhabdomyolysis	229.49	13.78	123	10236	40535	56241173
Drug hypersensitivity	71.83	13.78	157	10202	275048	56006660
Blood triglycerides increased	62.09	13.78	34	10325	11643	56270065
Coronary artery disease	56.07	13.78	46	10313	30750	56250958
Blood creatine phosphokinase increased	49.31	13.78	41	10318	27911	56253797
Myocardial infarction	48.78	13.78	72	10287	92798	56188910
Acute interstitial pneumonitis	43.16	13.78	12	10347	653	56281055
Cardiac failure congestive	37.68	13.78	62	10297	87658	56194050
Myalgia	37.42	13.78	78	10281	131947	56149761
Myopathy	37.35	13.78	23	10336	9789	56271919
Drug interaction	35.91	13.78	102	10257	209653	56072055
Cerebrovascular accident	34.61	13.78	64	10295	99206	56182502
Pancreatitis	31.27	13.78	40	10319	45040	56236668
Pancreatitis acute	28.90	13.78	29	10330	25095	56256613
Lip infection	28.57	13.78	6	10353	97	56281611
Rheumatoid arthritis	27.99	13.78	18	10341	382586	55899122
Hypertriglyceridaemia	25.68	13.78	15	10344	5801	56275907
Off label use	24.96	13.78	40	10319	556140	55725568
Drug intolerance	24.61	13.78	9	10350	264809	56016899
Blood glucose increased	24.38	13.78	47	10312	75104	56206604
Diabetes mellitus	22.26	13.78	37	10322	52698	56229010
Drug ineffective	20.79	13.78	93	10266	918896	55362812
Synovitis	19.84	13.78	3	10356	161302	56120406
Tendon rupture	19.71	13.78	14	10345	7556	56274152
Diabetes mellitus inadequate control	17.68	13.78	17	10342	13963	56267745
Hyperlipidaemia	17.42	13.78	19	10340	18090	56263618
Chronic kidney disease	17.07	13.78	29	10330	42027	56239681
Arthropathy	16.68	13.78	8	10351	200267	56081441
Infusion related reaction	16.42	13.78	9	10350	208922	56072786
Microalbuminuria	16.34	13.78	5	10354	381	56281327
Blood urea increased	15.85	13.78	21	10338	24452	56257256
Joint swelling	15.84	13.78	18	10341	289782	55991926
Bursitis	15.35	13.78	22	10337	27560	56254148
Bronchitis viral	15.22	13.78	6	10353	973	56280735
Infected bite	15.18	13.78	7	10352	1665	56280043
Maternal exposure during pregnancy	15.14	13.78	8	10351	189545	56092163
Angioedema	14.77	13.78	27	10332	41426	56240282
Transient ischaemic attack	14.76	13.78	24	10335	33553	56248155
Hypoglycaemia	14.66	13.78	32	10327	55783	56225925
Hypophagia	14.58	13.78	22	10337	28854	56252854
Blood creatine phosphokinase MB increased	14.19	13.78	6	10353	1163	56280545
Granulocytopenia	14.18	13.78	10	10349	5334	56276374
Wound	14.15	13.78	4	10355	138800	56142908
Myositis	14.06	13.78	12	10347	8456	56273252

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rhabdomyolysis	549.65	12.94	351	14429	63230	31619334
Acute kidney injury	114.80	12.94	337	14443	279377	31403187
Blood creatine phosphokinase increased	110.31	12.94	116	14664	41858	31640706
Blood triglycerides increased	107.96	12.94	71	14709	13326	31669238
Myalgia	99.00	12.94	149	14631	77109	31605455
Coronary artery disease	73.92	12.94	99	14681	45988	31636576
Myocardial infarction	61.66	12.94	152	14628	113302	31569262
Blood cholesterol increased	57.90	12.94	54	14726	16839	31665725
Drug hypersensitivity	56.07	12.94	112	14668	72487	31610077
Off label use	52.43	12.94	51	14729	347223	31335341
Polymyositis	52.34	12.94	21	14759	1394	31681170
Cardiac failure congestive	47.00	12.94	110	14670	79277	31603287
Drug interaction	40.38	12.94	198	14582	208345	31474219
Pancreatitis	37.48	12.94	63	14717	35708	31646856
International normalised ratio increased	30.46	12.94	66	14714	45157	31637407
Myopathy	30.27	12.94	31	14749	10821	31671743
Drug ineffective	28.05	12.94	93	14687	395480	31287084
Thunderclap headache	27.45	12.94	6	14774	43	31682521
Drug abuse	25.45	12.94	5	14775	87753	31594811
Hyperglycaemia	25.44	12.94	54	14726	36422	31646142
Chromaturia	25.11	12.94	31	14749	13267	31669297
Haemodialysis	25.00	12.94	27	14753	10018	31672546
Hypertriglyceridaemia	24.94	12.94	24	14756	7774	31674790
Chronic kidney disease	23.96	12.94	54	14726	37921	31644643
Granulocytopenia	23.84	12.94	21	14759	6078	31676486
Blood glucose increased	23.32	12.94	72	14708	61011	31621553
Drug level below therapeutic	23.04	12.94	19	14761	5029	31677535
Type 2 diabetes mellitus	21.03	12.94	30	14750	14754	31667810
General physical health deterioration	20.34	12.94	14	14766	113421	31569143
Myositis	19.57	12.94	25	14755	11069	31671495
Angina unstable	19.39	12.94	25	14755	11170	31671394
Angioedema	19.23	12.94	46	14734	33572	31648992
Blood glucose decreased	18.77	12.94	26	14754	12445	31670119
Erosive duodenitis	18.11	12.94	10	14770	1366	31681198
Product use in unapproved indication	18.09	12.94	12	14768	99159	31583405
Death	17.95	12.94	97	14683	360472	31322092
Treatment noncompliance	17.88	12.94	38	14742	25646	31656918
Hyperlipidaemia	17.69	12.94	26	14754	13134	31669430
Tricuspid valve incompetence	17.35	12.94	21	14759	8808	31673756
Lacrimation decreased	16.72	12.94	3	14777	6	31682558
Pyrexia	16.67	12.94	79	14701	303761	31378803
Iron deficiency anaemia	16.37	12.94	21	14759	9338	31673226
Fanconi syndrome	16.35	12.94	10	14770	1652	31680912
Muscular weakness	16.25	12.94	67	14713	65381	31617183
Asthenia	16.22	12.94	168	14612	224587	31457977
Blood creatinine increased	16.05	12.94	83	14697	88995	31593569
Reversible cerebral vasoconstriction syndrome	15.60	12.94	6	14774	356	31682208
Pneumonia haemophilus	15.47	12.94	6	14774	364	31682200
Otitis externa	15.05	12.94	8	14772	1013	31681551
Interstitial lung disease	14.93	12.94	5	14775	61398	31621166
Arteriosclerosis coronary artery	14.86	12.94	22	14758	11186	31671378
Chest pain	14.63	12.94	99	14681	116858	31565706
Metabolic acidosis	14.49	12.94	46	14734	39531	31643033
Breast neoplasm	14.48	12.94	3	14777	16	31682548
Renal tubular necrosis	14.14	12.94	25	14755	14734	31667830
Coronary artery stenosis	14.11	12.94	19	14761	8851	31673713
Hyperlactacidaemia	13.93	12.94	11	14769	2739	31679825
Intentional product use issue	13.91	12.94	3	14777	49344	31633220
Aortic valve sclerosis	13.74	12.94	7	14773	813	31681751
Paralysis	13.70	12.94	15	14765	5648	31676916
Supraventricular tachycardia	13.33	12.94	20	14760	10287	31672277

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rhabdomyolysis	726.65	12.24	412	20366	95348	70812318
Blood triglycerides increased	168.85	12.24	92	20686	19572	70888094
Blood creatine phosphokinase increased	163.84	12.24	139	20639	61124	70846542
Coronary artery disease	141.05	12.24	129	20649	62607	70845059
Acute kidney injury	133.47	12.24	371	20407	474253	70433413
Myocardial infarction	124.19	12.24	198	20580	171447	70736219
Myalgia	120.54	12.24	193	20585	167699	70739967
Drug hypersensitivity	85.52	12.24	217	20561	262242	70645424
Cardiac failure congestive	81.55	12.24	144	20634	135313	70772353
Drug interaction	76.15	12.24	265	20513	381176	70526490
Off label use	72.28	12.24	67	20711	742993	70164673
Myopathy	61.90	12.24	48	20730	18564	70889102
Pancreatitis	60.69	12.24	83	20695	62585	70845081
Drug ineffective	52.15	12.24	125	20653	939627	69968039
Polymyositis	46.53	12.24	21	20757	2980	70904686
Hypertriglyceridaemia	44.90	12.24	33	20745	11778	70895888
Hyperlipidaemia	43.97	12.24	44	20734	23819	70883847
Granulocytopenia	43.33	12.24	31	20747	10616	70897050
Rheumatoid arthritis	42.79	12.24	16	20762	291789	70615877
Myositis	37.40	12.24	35	20743	17454	70890212
Hyperglycaemia	36.63	12.24	67	20711	64605	70843061
Chromaturia	35.51	12.24	39	20739	23489	70884177
Blood glucose increased	34.33	12.24	86	20692	102896	70804770
Blood cholesterol increased	34.18	12.24	65	20713	64539	70843127
International normalised ratio increased	34.13	12.24	74	20704	80652	70827014
Drug intolerance	33.71	12.24	12	20766	225675	70681991
Chronic kidney disease	31.77	12.24	61	20717	60996	70846670
Acute interstitial pneumonitis	31.63	12.24	12	20766	1098	70906568
Blood creatinine increased	29.86	12.24	101	20677	142900	70764766
Angioedema	29.23	12.24	62	20716	66548	70841118
Muscular weakness	28.26	12.24	97	20681	138239	70769427
Drug abuse	27.40	12.24	5	20773	147251	70760415
Pancreatitis acute	27.07	12.24	48	20730	45176	70862490
Treatment failure	26.59	12.24	5	20773	144137	70763529
Haemodialysis	26.58	12.24	29	20749	17337	70890329
Cerebrovascular accident	26.23	12.24	97	20681	143373	70764293
Pyrexia	26.03	12.24	91	20687	606861	70300805
Renal failure	25.98	12.24	117	20661	188953	70718713
Angina unstable	25.13	12.24	27	20751	15866	70891800
Blood glucose decreased	24.90	12.24	33	20745	24126	70883540
Hypoglycaemia	24.62	12.24	72	20706	94292	70813374
General physical health deterioration	24.39	12.24	20	20758	236011	70671655
Joint swelling	24.31	12.24	23	20755	253188	70654478
Lip infection	22.70	12.24	6	20772	167	70907499
Infusion related reaction	22.66	12.24	15	20763	197519	70710147
Lower respiratory tract infection	22.63	12.24	3	20775	111910	70795756
Acute myocardial infarction	22.35	12.24	59	20719	72828	70834838
Treatment noncompliance	21.19	12.24	44	20734	46530	70861136
Coronary artery stenosis	20.59	12.24	21	20757	11623	70896043
Chest pain	20.58	12.24	135	20643	251125	70656541
Thunderclap headache	20.46	12.24	6	20772	246	70907420
Cardiac disorder	20.19	12.24	50	20728	59365	70848301
Erosive duodenitis	20.16	12.24	10	20768	1752	70905914
C-reactive protein increased	20.03	12.24	4	20774	110513	70797153
Renal cyst	19.93	12.24	22	20756	13323	70894343
Arteriosclerosis coronary artery	19.64	12.24	24	20754	16191	70891475
Type 2 diabetes mellitus	19.30	12.24	41	20737	44039	70863627
High density lipoprotein decreased	19.11	12.24	13	20765	4106	70903560
Product use issue	18.89	12.24	15	20763	179922	70727744
Hyperkalaemia	18.59	12.24	71	20707	106520	70801146
Blood urea increased	18.17	12.24	41	20737	45868	70861798
Metabolic acidosis	17.76	12.24	55	20723	74291	70833375
Hypophagia	17.44	12.24	38	20740	41532	70866134
Intervertebral disc displacement	17.12	12.24	6	20772	438	70907228
Condition aggravated	16.43	12.24	67	20711	427568	70480098
Tricuspid valve incompetence	16.34	12.24	23	20755	17794	70889872
Blood creatine phosphokinase MB increased	16.17	12.24	10	20768	2687	70904979
Fanconi syndrome	16.12	12.24	10	20768	2703	70904963
Maternal exposure during pregnancy	15.79	12.24	7	20771	115338	70792328
Coronary artery occlusion	15.41	12.24	20	20758	14325	70893341
Intentional product use issue	15.36	12.24	8	20770	120134	70787532
Myoglobinuria	15.28	12.24	7	20771	1028	70906638
Wound	15.16	12.24	5	20773	98727	70808939
Carotid artery stenosis	14.83	12.24	15	20763	8221	70899445
Ischaemic cardiomyopathy	14.77	12.24	14	20764	7090	70900576
Product complaint	14.64	12.24	18	20760	12213	70895453
Hypercholesterolaemia	14.60	12.24	22	20756	18095	70889571
Iron deficiency anaemia	14.47	12.24	25	20753	23047	70884619
Bursitis	14.30	12.24	27	20751	26646	70881020
Tendon rupture	14.29	12.24	17	20761	11152	70896514
Acute coronary syndrome	14.25	12.24	23	20755	20056	70887610
Alopecia	13.84	12.24	23	20755	198467	70709199
Diabetes mellitus inadequate control	13.50	12.24	24	20754	22621	70885045
Diabetes mellitus	13.48	12.24	49	20729	71775	70835891
Aspartate aminotransferase increased	13.45	12.24	73	20705	126905	70780761
Peripheral swelling	13.40	12.24	31	20747	236532	70671134
Erectile dysfunction	13.17	12.24	18	20760	13544	70894122
Hepatic steatosis	13.16	12.24	30	20748	33783	70873883
Blindness	13.06	12.24	24	20754	23203	70884463
Mitral valve incompetence	13.04	12.24	26	20752	26702	70880964
Asthenia	12.98	12.24	197	20581	457469	70450197
Otitis externa	12.71	12.24	8	20770	2219	70905447
Liver function test abnormal	12.58	12.24	43	20735	61103	70846563
Hyperlactacidaemia	12.51	12.24	11	20767	5061	70902605
Pneumonia haemophilus	12.47	12.24	6	20772	984	70906682
Aortic valve sclerosis	12.41	12.24	7	20771	1590	70906076
Infected bite	12.37	12.24	7	20771	1600	70906066
Myocardial ischaemia	12.36	12.24	24	20754	24176	70883490

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AB04	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Fibrates
FDA CS	M0199111	PPAR alpha
FDA MoA	N0000175375	Peroxisome Proliferator-activated Receptor alpha Agonists
FDA EPC	N0000175596	Peroxisome Proliferator Receptor alpha Agonist
CHEBI has role	CHEBI:35679	antilipemic drugs
MeSH PA	D000963	Antimetabolites
MeSH PA	D065687	Cytochrome P-450 CYP2C8 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D000960	Hypolipidemic Agents
MeSH PA	D057847	Lipid Regulating Agents
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertriglyceridemia	indication	302870006
Primary Prevention of Coronary Heart Disease	indication
Hypoalphalipoproteinemia	off-label use	190785000
Primary biliary cirrhosis	contraindication	31712002	DOID:12236
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Acute nephropathy	contraindication	58574008
Leukopenia	contraindication	84828003	DOID:615
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Calculus in biliary tract	contraindication	266474003
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.13	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Peroxisome proliferator-activated receptor alpha	Nuclear hormone receptor	Q07869	PPARA_HUMAN	AGONIST	EC50	4.23	IUPHAR	CHEMBL
Transthyretin	Secreted	P02766	TTHY_HUMAN		Kd	7	CHEMBL
Cytochrome P450 2C8	Enzyme	P10632	CP2C8_HUMAN		Ki	5.74	WOMBAT-PK
Lipoprotein lipase	Enzyme	P06858	LIPL_HUMAN				WOMBAT-PK
CDGSH iron-sulfur domain-containing protein 1	Unclassified	Q9NZ45	CISD1_HUMAN		Ki	5.14	CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		Ki	4.52	WOMBAT-PK
Fatty acid-binding protein, liver	Unclassified		FABPL_RAT		Ki	5.73	CHEMBL

External reference:

ID	Source
4018639	VUID
N0000146952	NUI
D00334	KEGG_DRUG
4018639	VANDF
C0017245	UMLSCUI
CHEBI:5296	CHEBI
4TX	PDB_CHEM_ID
CHEMBL457	ChEMBL_ID
DB01241	DRUGBANK_ID
D015248	MESH_DESCRIPTOR_UI
3463	PUBCHEM_CID
3439	IUPHAR_LIGAND_ID
3899	INN_ID
Q8X02027X3	UNII
4719	RXNORM
4778	MMSL
523	MMSL
d00245	MMSL
002050	NDDF
35282000	SNOMEDCT_US
387189002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lopid	HUMAN PRESCRIPTION DRUG LABEL	1	0071-0737	TABLET, FILM COATED	600 mg	ORAL	NDA	18 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9130	TABLET, FILM COATED	600 mg	ORAL	ANDA	17 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9707	TABLET, FILM COATED	600 mg	ORAL	ANDA	18 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8354	TABLET, FILM COATED	600 mg	ORAL	ANDA	15 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8354	TABLET, FILM COATED	600 mg	ORAL	ANDA	15 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	10544-569	TABLET, FILM COATED	600 mg	ORAL	ANDA	18 sections
Gemfibrozil	Human Prescription Drug Label	1	16571-784	TABLET, FILM COATED	600 mg	ORAL	ANDA	15 sections
Gemfibrozil	Human Prescription Drug Label	1	16714-101	TABLET	600 mg	ORAL	ANDA	18 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	21695-732	TABLET, FILM COATED	600 mg	ORAL	ANDA	17 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	24658-260	TABLET, FILM COATED	600 mg	ORAL	ANDA	17 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	31722-128	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	31722-225	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	33261-146	TABLET, FILM COATED	600 mg	ORAL	ANDA	17 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	42806-260	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-745	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-745	TABLET	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	43063-921	TABLET	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	43063-921	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43353-090	TABLET, FILM COATED	600 mg	ORAL	ANDA	18 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	43353-772	TABLET, FILM COATED	600 mg	ORAL	ANDA	21 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	43602-452	TABLET	600 mg	ORAL	ANDA	10 sections
Gemfibrozil	Human Prescription Drug Label	1	50090-2450	TABLET, FILM COATED	600 mg	ORAL	ANDA	15 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2902	TABLET	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5808	TABLET	600 mg	ORAL	ANDA	11 sections
GEMFIBROZIL	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5808	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	50268-350	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	51138-588	TABLET, FILM COATED	600 mg	ORAL	ANDA	18 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	51655-142	TABLET	600 mg	ORAL	ANDA	9 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	51655-143	TABLET	600 mg	ORAL	ANDA	11 sections
Gemfibrozil	HUMAN PRESCRIPTION DRUG LABEL	1	53002-1068	TABLET	600 mg	ORAL	ANDA	11 sections